Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has excellent clinical activity in patients with chronic lymphocytic leukemia (CLL). Characteristically, ibrutinib causes CLL cell redistribution from tissue sites into the peripheral blood during the initial weeks of therapy. To better characteri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wodarz, Dominik, Garg, Naveen, Komarova, Natalia L., Benjamini, Ohad, Keating, Michael J., Wierda, William G., Kantarjian, Hagop, James, Danelle, O’Brien, Susan, Burger, Jan A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123432/
https://ncbi.nlm.nih.gov/pubmed/24829205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-554220
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados